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ABSTRACT

Henseler, Rebecca A. M.S., Department of Biological Sciences, 2007.
Modulation of the 3’IgH Regulatory Region (3’IgH RR), a prospective in vitro screening
tool for identifying potential immunotoxicants.

The immune system is critical to human survival. However, assessing alterations
of immune function by potential immunotoxicants is complicated by the diffuse nature of
the immune system, which is composed of various effector cells each with differing
effector functions. Current immunotoxicity testing is limited to animal studies. We have
developed a model, which may provide an in vitro alternative to animal studies in
identifying immunotoxicants that specifically target B cell function (i.e., alteration of
immunoglobulin (Ig) or expression and antibody secretion). This model consists of a
well-characterized B cell line, CH12.LX, which appears to appropriately model primary
B cell function. We have stably transfected the CH12.LX cell line with a transgene
regulated by an enhancer, the 3’Ig heavy chain regulatory region (3’IgH RR), purported
to control Ig heavy chain gene expression. Our previous work has identified the 3’IgH
RR as a sensitive target of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) possibly
mediated by activation of the aryl hydrocarbon receptor (AhR) signaling pathway. We
have tested our model with several structurally diverse chemicals shown to activate the
AhR signaling pathway and found an association between AhR activation and inhibition
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of both 3’IgH RR activation and Ig protein expression. We have also tested two
chemicals previously shown to activate humoral immunity through non-AhR receptors.
Results indicate that our model appropriately identifies immunomodulators of two
receptor-signaling pathways, each leading to altered immunoglobulin expression.
(Supported by the Colgate-Palmolive Grants for Alternative Research and the Boonshoft
School of Medicine, WSU)
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I.

2,3,7,8-TETRACHLORODIBENZO-p-DIOXIN
Dioxin is a term used to refer to a class of chemicals that have similar structures

and a common route of action. This class includes polychlorinated dibenzodioxins,
dibenzofurans, and biphenyls. These chemicals have been ubiquitous environmental
contaminants since the beginning of the 20th century but have not been viewed as a
concern until the past thirty years. Human exposure usually occurs through consumption
of contaminated food, air, or through inhalation of dust and smoke (Mandal 2005). Prior
to the enforcement of specific environmental regulations the major sources of dioxins
were through the production of the pesticides, 2,4,5-tricholorophenoxyacetic acid and
2,4-dichlorophenoxyacetic acid, and paper bleaching. The knowledge of these types of
contamination has led to banning of certain pesticides and development of new ways to
bleach paper. Dioxins are still a concern today, but now the primary source of dioxins
has shifted to combustion processes where dioxins are a secondary product. Dioxins are
a concern to our environment, because of the implications that they have on animal and
human

welfare,

which

include

reproductive

toxicity,

neurotoxicity,

potential

carcinogenicity, and immunotoxicity (Mandal 2005). The hallmark of this family of
contaminants is 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). This chemical is believed
to be one of the most potent and dangerous of chemicals in this family, and in turn has
gained the most concern and research devoted to it. Some of the documented toxicities
that occur with exposure to TCDD are loss of body weight, teratogenicity, porphyria,
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chloracne, tumor promotion, disruption in endocrine homeostasis, and immunotoxicity
(Poland and Knutson 1982; Mandal 2005). The effects of TCDD and other dioxins are
believed to be mediated through binding to the aryl hydrocarbon receptor (AhR) and
influencing gene expression (Mandal 2005).

2

II.

ARYL HYDROCARBON RECEPTOR
The aryl hydrocarbon receptor (AhR) is an intracellular protein that is part of the

helix-loop-helix PER-ARNT-SIM (PAS) family. The PAS family of proteins play an
essential role in the metabolism of xenobiotic compounds, adaptation to hypoxia, and the
regulation of circadian rhythm (Gu, Hogenesch et al. 2000). The AhR is a ubiquitous
protein that is present in the cytoplasm of most cells and is complexed with other proteins
including HSP 90 until activated by ligand. TCDD is one of the most studied ligands of
the AhR and is frequently used to study the AhR signaling pathway. Once bound by a
ligand, the AhR dissociates from the cytosolic complex and translocates to the nucleus
where it heterodimerizes with the AhR nuclear translocator (ARNT) protein.

The

AhR/ARNT complex then functions as a regulator of gene transcription by binding to
dioxin responsive enhancers (DRE) within sensitive genes (Denison, Fisher et al. 1989).
The most thoroughly studied gene regulated by TCDD-induced activation of the AhR
signaling pathway is cytochrome P4501A1 (CYP1A1). However, increasing evidence
supports a role of the AhR in many of the toxic effects induced by TCDD, including
immunotoxicity. (Figure 1)
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III.

BASIC IMMUNOLOGY
Immunology is the study of how the body reacts to foreign or non-self substances

referred to as antigens which include viral, bacterial, fungal, parasitic and any nonself
proteins or substances. The body has two combating forces against these infectious
agents that help to prevent infection: the innate and adaptive immune responses. Innate
immunity is the body’s first line of defense, and is characterized as non-specific, rapid
(i.e., reacts within minutes of invasion) and short-term protection. Its main physiological
function is to destroy intruding microorganisms through a non-specific process carried
out mainly by macrophages and neutrophils that clear pathogens by phagocytosis and
proteolysis. Tissue macrophages are the first to encounter pathogens that have broken
through the protective epithelial layer. Pathogen-activated macrophages begin to release
proteins known as cytokines that initiate an inflammatory response, resulting in the
recruitment of neutrophils to the site of infection. If the infection is unsuccessfully
cleared by the innate immune response, the adaptive immune response becomes activated
to clear the infection. Adaptive immunity can be defined as a specific and diversified
response to individual antigens, which offers long-term protection through the generation
of immunologic memory, a process that elicits a quicker response to future encounters by
the same antigen.
Adaptive immunity is primarily mediated by T cells and B cells that originate in
the bone marrow. B cells will remain in the bone marrow for maturation until they are
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distributed to peripheral lymphoid organs. T cells, on the other hand, originate in the
bone marrow than migrate to the thymus to complete maturation, followed by recruitment
to peripheral lymphoid organs.

Both cells are capable of specific antigen recognition,

resulting in each individual B or T cell recognizing only one antigen determinant. Both B
and T cells have effector molecules that aid in the fight against the intruding antigens. T
cells release cytokines in response to foreign pathogens, while B cells are capable of
secreting antibodies in response to an antigen. T cells and B cells work together at times
in the clearance of antigen. Both B cells and T cells have surface receptors that aid in the
recognition of an antigen. On a B cell there is the B cell receptor, which is responsible for
recognition of the specific antigen. This receptor is composed of a membrane bound
immunoglobulin (referred to as an antibody in its secreted form) which is associated in a
noncovalent complex with Igα and Igβ chains. The B cell receptor sends signals to the B
cell once it has bound an antigen, and either directly activates the B cell to proliferate and
differentiate into antibody secreting cells or leads to presentation of the antigen via MHC
class II surface molecules to helper T cells, which secrete proteins (cytokines) that cause
the B cell to proliferate and differentiate into antibody secreting cells.
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IV.

B CELLS AND ANTIBODY PRODUCTION
B cells, major effector cells in adaptive immunity, have the primary function of

producing and secreting high concentrations of antibodies that can specifically bind and
clear invading antigens from the body. Each B cell makes antibodies with only one
antigen specificity and will only produce antibodies when activated by that specific
antigen. The basic immunoglobulin (Ig) is composed of two heavy chains and two light
chains. Each chain can be further broken down into variable regions and constant
regions.

The variable region determines the antigen specificity and also forms the

antigen binding site. Binding sites for the antigen are formed from a composite of one
light and one heavy chain. Since Ig is composed of two heavy chains and two light
chains, there are two antigen binding sites.

There are five major isotypes of Ig (IgG,

IgM, IgA, IgD, and IgE), each defined by its heavy chain constant region (CH), which is
represented by lower-case Greek letters as follows: IgG=Cγ, IgM=Cμ, IgA=Cα, IgD=Cδ,
and IgE=Cε. IgG can be further broken down into four subclasses (IgG1, IgG2, IgG3,
and IgG4 for humans; IgG1, IgG2a, IgG2b, and IgG3 for mice), and in humans there are
two subclasses of IgA (IgA1 and IgA2), which is not true for mice (one IgA class). All
naive B cells express IgM and IgD on their cell surface, but the early stages of an
antibody response are dominated by IgM production and secretion. Later on in the
response or upon a second encounter with the same antigen, production of IgG or IgA
will dominate the antibody response. Isotype switching from IgM to IgG or IgA occurs
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through a DNA recombination process called class switch recombination in which the
heavy chain variable (V) region becomes associated with a different CH region resulting
in the deletion of DNA between these regions and somatic recombination.

Isotype

switching does not alter antibody specificity but instead has an effect on the functions
that an antibody can engage, resulting in a quicker and stronger antibody response.
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V.

IMMUNE EFFECTS INDUCED BY TCDD
TCDD is one of the most studied of the dioxins, and effects on the immune

system appear to be one of the most sensitive endpoints of TCDD toxicity (Kerkvliet
2002). Studies of altered immune function by TCDD date all the way back to the 1970’s
when innate, humoral and cell-mediated immunity of rodents was shown to be directly
impacted by exposure to TCDD. Past studies also showed that rodents who encountered
doses of TCDD were more susceptible to disease, unable to reject transplanted tumors,
and tumor growth and metastasis increased (Holsapple, Morris et al. 1991; Kerkvliet
2002) . TCDD has been shown to have a negative influence on various cells of the
immune system including T and B cells (Kerkvliet 2002). The alterations of T cell
immunity include decreased production of cytotoxic T lymphocytes, thymic atrophy, and
suppressed hypersensitivity responses (Kerkvliet 2002) .

The B cell has also been

identified as a direct target of TCDD exposure. In the sheep red blood cell (SRBC)
assay, in which SRBC’s activate B cells through the required help of T cells and
macrophages, TCDD has been shown to inhibit this response (Dooley and Holsapple
1988). However, TCDD has also been shown to directly inhibit B cell differentiation into
plasma cells when activated by lipopolysaccharide (LPS) (Dooley and Holsapple 1988).
LPS is a complex lipid structure found in the outer membrane of most gram negative
bacteria which can activate and differentiate B cells in the absence of T cells and
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macrophages. Therefore, B cells are a direct target of TCDD exposure (Dooley and
Holsapple 1988)
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VI.

AHR AND B CELLS
Previous studies have shown that TCDD is capable of binding to the AhR in

murine B cells and inhibiting B cell differentiation and antibody secretion, and this
inhibition is proposed to be mediated by the AhR (Marcus, Holsapple et al. 1998;
Sulentic, Holsapple et al. 1998; Sulentic, Holsapple et al. 2000). This hypothesis has
been tested in a number of different studies including one study that tested two different
B cell lines, one that expresses high levels of AhR (CH12.LX) and one that lacks AhR
expression (BCL-1). Only the CH12.LX cell line showed TCDD-induced inhibition of Ig
heavy chain expression and secretion, which appeared to be mediated through binding of
the AhR to DRE motifs (Sulentic, Holsapple et al. 1998; Sulentic, Holsapple et al. 2000).
Further investigation of the role of the AhR was shown in an AhR knockout mouse study.
This study showed that AhR-deficient and wildtype mice (both from the same strain of
mouse) were capable of normal cell-mediated and humoral immune responses when
presented with an antigen, but when dosed with TCDD, the antibody immune response in
the AhR-deficient mice was refractory to suppression (Vorderstrasse, Steppan et al.
2001). This outcome suggests a key role of the AhR in the dysregulation of B cell
function by TCDD. Furthermore, studies have identified DRE binding sites within a 3’
region of the Ig heavy chain gene (only expressed in B cells), known as the 3’Ig heavy
chain regulatory region, which may mediate TCDD-induced inhibition of Ig heavy chain
expression and Ig secretion (Sulentic, Holsapple et al. 2000).
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VII.

3’IMMUNOGLOBULIN HEAVY CHAIN REGULATORY REGION
One important gene within B cells is the Ig heavy chain gene. Regulation of this

gene is accomplished by several elements that include a VH promoter that lies upstream of
a variable region and is responsible for regulation of Ig heavy chain (IgH) gene
expression; a Eμ region that lies in between the variable region and the μ constant region
(Cμ) and is responsible for regulating VDJ joining (Calame and Eaton 1988; Serwe and
Sablitzky 1993); and most recently discovered a 40-kb region 3’ of the α constant region
(Cα) known as the 3’Ig heavy chain regulatory region (3’IgH RR). The 3’IgH RR is
believed to play an important role in Ig heavy chain expression and class switch
recombination (Lieberson, Giannini et al. 1991). (Figure 2)
The 3’IgH RR is composed of four separate hypersensitive regulatory domains
(hs3, hs1,2, hs3B, hs4), with the first three domains being active mainly in mature B-cells
and the hs4 enhancer active throughout the lifespan of a B cell (Chauveau, Pinaud et al.
1998). There are several binding sites within the 3’IgH RR for transcription factors that
appear to regulate its activity. These transcription factors include B cell specific activator
protein (BSAP), NF-κB, octamer (OCT), OCA- B, and AP-1.

As mentioned above,

DRE motifs have also been identified within the 3’IgH RR (Sulentic, Holsapple et al.
2000). TCDD was shown to induce AhR-DRE binding within the 3’IgH RR as well as
inhibition of 3’IgH RR activity, which correlates with TCDD-induced inhibition of μ
heavy chain expression and IgM secretion (Sulentic, Holsapple et al. 2000; Sulentic,
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Zhang et al. 2004). Since structurally diverse chemicals from dietary, pharmaceutical
and industrial origin have been demonstrated to activate the AhR signaling pathway, a
potential AhR-mediated modulation of 3’IgH RR activity may have broad toxicological
implications. The primary focus of the research reported here was to test this premise by
utilizing an in vitro B cell line model and assessing the effects of several chemicals,
including a diverse array of AhR and non-AhR ligands on transcriptional activity
mediated by the 3’IgH RR.
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VIII. AhR AGONISTS
The chemicals were chosen based on previous studies that have demonstrated
activation of the AhR, whether indirect or direct. Historically, the ligands that bind to the
AhR have had the characteristics of being planar, aromatic, and hydrophobic as in the
case of TCDD, but recently other chemicals that associate with the AhR deviate from this
set of characteristics (Denison and Nagy 2003). Chemicals were also chosen in a manner
that would provide a selection of structurally diverse chemicals ranging from dietary,
pharmaceutical, and environmental origin. These may have a higher potential of human
exposure than the historic ligands that have been shown to activate the AhR signaling
pathway.
A.

Indolo(3,2,b)carbazole

Indolo(3,2,b)carbazole (ICZ) is an important chemical when considering immune
regulation because of its similarity to TCDD, which include structural and functional
similarities. Two important deviations from TCDD include the lack of halogens and low
lipophilicity, which results in lower accumulation in cells than TCDD. ICZ is a dietary
breakdown product of indole-3-carbinol that is present in cruciferous vegetables such as
brussel sprouts and broccoli. ICZ is catalyzed from indole-3-carbinol in the acid
environment of the stomach, or it can also be produced as a metabolic product of
intestinal bacteria from trytophan (Chen, Riby et al. 1995). A previous study showed that
people who consume 100 grams of cruciferous vegetables a day will in turn be producing
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1.3μg of ICZ (Bjeldanes, Kim et al. 1991). In comparison with TCDD, ICZ is capable of
inducing CYP1A1 at a rate of 103-104 less than TCDD (Chen, Riby et al. 1995).
Furthermore, ICZ has an affinity for the AhR that is approximately 3.7x102 lower than
TCDD and induces nuclear translocation of the AhR 100 times lower than TCDD
(Pohjanvirta, Korkalainen et al. 2002)
B.

Omeprazole

Acid reflux related diseases are an increasing problem for the human population
with a total of 2.3% of the US population being affected. The choice of therapy had been
histamine-2-receptor agonists, but has recently shifted to proton pump inhibitors
(Robinson 2005). Omeprazole is one of the main proton pump inhibitors used, and
mechanistically it works by inhibiting the H+/K+-ATPase in gastric parietal cells
(Quattrochi and Tukey 1993). The use of this medication is given in tablet form of up to
40mg, which can result in a plasma concentration of more that 5.21μM (PDR 2006).
Structurally, Omeprazole is planar with a sulfoxide-containing chain connecting a
benzimidazole ring and a substituted pyridine ring. The planarity matches one of the
hallmark characteristics of being a ligand for the AhR (Dzeletovic, McGuire et al. 1997).
Previous studies have shown Omeprazole to be capable of inducing CYP1A1, but they
have failed to show direct binding to the AhR based on competitive binding studies.
Contrary to a lack of AhR binding, within this study Omeprazole was shown to induced
nuclear translocation of the AhR and DRE binding in rat hepatocytes (Lemaire,
Delescluse et al. 2004)
C.

Carbaryl

14

Carbaryl is a common insecticide that humans come into contact with through the
consumption of water, plants or fish that have absorbed some of the chemical. Most
people are not in direct danger of exposure to Carbaryl, but instead it is mainly a threat to
the workers who produce it and are in daily contact with it. This is because of the steady
deterioration of the chemical and its short half life. It has been shown that possible
Carbaryl exposure of formulators and applicators can range from 59-74mg/hr through the
dermal route and up to 1mg/hr through respiration (Comer, Staiff et al. 1975). Carbaryl
has been shown to induce CYP1A1 through an AhR-dependent mechanism, and has been
shown to directly bind the AhR.

Even though this chemical is neither planar, nor

polycyclic aromatic, it is considered a weak agonist that is about 3x105 fold less potent
than TCDD (Denison, Phelan et al. 1998).
D.

Primaquine

Malaria is a very serious disease. According to the Centers for Disease Control
and Prevention (CDC), 350-500 million cases of malaria occur worldwide with over two
million people dying each year. Primaquine has been the drug treatment of choice and
cure for relapse of Plasmodium vivax and ovale blood stage infections. Primaquine has
been used as a treatment for malaria since 1952 and has remained the hallmark treatment
for malaria when compared to any other recently discovered treatments(Hill, Baird et al.
2006) . This drug has been shown to have adverse effects at high dosages, which include
methaemoblobinaemia and haemolytic anaemia (Fontaine, Delescluse et al. 1999).
Previous studies in hepatoma cells have demonstrated AhR activation and CYP1A1
induction following Primaquine treatment. Primaquine has an affinity for the AhR at
approximately 5x105 times less than TCDD but is able to displace TCDD from the AhR
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(Backlund and Ingelman-Sundberg 2004). Primaquine is usually given in 15 or 30 mg
tablets for 14 days and studies have shown that after an acute dosage of 15mg there was a
peak concentration of 65.0 ng/ml (0.25μM) (Ward, Mihaly et al. 1985).
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IX.

NON-AhR AGONISTS
The chemicals listed above all work through the AhR receptor; however,

regulation of the 3’IgH RR and Ig expression as reviewed above may involve multiple
transcription factors. We chose to look at two chemicals that work through different
receptors that are expressed in B cells.
A.

Carbachol

Carbachol is a cholinergic agonist for the muscarinic and nicotinic receptors. It is
commonly used in the treatment of glaucoma. Glaucoma is a serious eye disease in
which the intraocular pressure in the eye is elevated. Carbachol is prescribed as drops
that produce constriction of the iris and ciliary body resulting in the reduction of ocular
pressure associated with glaucoma (Duncan and Collison 2003). In a previous study
Carbachol was shown to increase the T-cell dependent IgM response to sheep red blood
cells (Pruett, Han et al. 1992). Both T and B cells express cholinergic receptors (Sato,
Fujii et al. 1999; Skok, Grailhe et al. 2005) .
B.

Terbutaline

Terbutaline is an agonist for the β2-adrenergic receptor, which is present on Bcells. It is a commonly prescribed drug for the treatment of many lung diseases, such as
asthma or emphysema, to help eliminate shortness of breath by opening up airway
passages (Sears and Lotvall 2005).

In previous studies Terbutaline has been shown to
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enhance Ig expression in B cells through the induction of OCA-B binding to octomer
binding sites within the 3’IgH (Podojil, Kin et al. 2004; Podojil and Sanders 2005).
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X.

SIGNIFICANCE AND OBJECTIVES
The purpose of this research was to determine the effect on 3’IgH RR activity of

structurally diverse chemicals from dietary, environmental, or pharmaceutical origin
which induce the AhR signaling pathway. Previous results from this lab have identified
the 3’IgH RR as a sensitive target of TCDD. This study determined if inhibition of 3’IgH
RR is unique to TCDD or if other chemicals (ICZ, Omeprazole, Carbaryl, and
Primaquine) that activate the AhR signaling pathway also target 3’IgH RR. Since TCDD
represents a broad class of chemicals and increasing evidence suggests that the spectrum
of potential AhR ligands is much broader than typical halogenated hydrocarbons, the
potential for AhR-mediated inhibition of 3’IgH RR activity is of great toxicological
significance to human health and maintaining immunocompetence mediated by
antibodies.
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XI.

MATERIALS AND METHODS
A.

Chemicals

Omeprazole, Primaquine, Carbaryl, Carbachol, and Terbutaline were all purchase
through Sigma Aldrich (Milwaukee, WI).

Chemical purities were as followed:

Primaquine (98.9%), Carbaryl (99.8%), Omeprazole (100%), Carbachol (>99%), and
Terbutaline (>99%) Indolo(3,2,b)carbazole was generously donated by Dr. Leonard F.
Bjeldanes, (University of California, Berkely, CA). LPS (Sigma) was used as a B cell
stimulant in all experiments.
B.

Cell line model

The CH12.LX murine B cell line was utilized in the transient transfection
experiments with a luciferase reporter regulated by the 3’IgH RR.

This cell line,

previously characterized by Bishop and Haughton (Bishop and Haughton 1986), was
derived from the murine CH12 B cell lymphoma that arose in B10.H-2aH-4bp/Wts mice
(B10.A x B10.129) and was a generous gift from Dr. Geoffrey Haughton (University of
North Carolina, Chapel Hill, NC).

To more closely resemble the endogenous IgH

chromosome, a modified version of the CH12.LX cell line (CH12.γ2b-3’IgH) that stably
expresses a γ2b transgene regulated by the 3’IgH RR was also utilized. The γ2b minilocus (Shi and Eckhardt 2001) that our lab used in making the CH12.γ2b-3’IgH cell line
was generously donated by Dr. Laurel Eckhardt (Hunter College of the City University of
New York, New York, NY).
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C.

Transient transfection

Transient transfections were performed as followed: CH12.LX cells (2.2x107)
were resuspended into 440μl of culture media with 22μg 3’IgH RR or VH reporter
plasmid. 200uL of the solution was then transferred to two 2-mm gap electroporation
cuvettes. Cells were electroporated using an electro cell manipulator (ECM 630) with the
voltage at 250 volts, the capacitance at 250μF, and the resistance at 300 ohms. The total
400μL electroporated solution was then resuspended into 3.6ml of culture media (5.0x106
cells). 280μL of the resuspended solution was then added to 7 tubes containing 6.72mL
of culture media each, resulting in 2x105 cells/ml. CH12.LX cells were immediately
treated with or without LPS and ICZ, Carbaryl, Omeprazole, Primaquine, Carbachol,
Terbutaline, TCDD, or DMSO. 2ml from each tube were aliquoted into 12-well plates
for triplicate samples at a concentration of 2.0x105 cells/ml. The 12-well plates were
incubated at 37°C, 5% CO2 for 48hr. After the 48hr incubation period, cells were lysed
using 1x reporter lysis buffer. The samples were immediately frozen at -80°C. To
measure luciferase enzyme activity, samples were thawed at room temperature then
centrifuged at 14,000 RPM at 4°C for 5 min. The lysate was transferred to new tubes, and
20μl of lysate was analyzed with a luminometer (Berthold detection systems, Sirius).
The luciferase activity was represented as relative light units.
D.

Analysis

of

γ2b

gene

and

Ig

protein

by

Enzyme-Linked

Immunosorbent Assay (ELISA)
For both the γ2b transgene and Ig protein analysis, stably transfected CH12.LX
cells were treated with LPS and ICZ, Omeprazole, Carbaryl, Primaquine, Carbachol,
Terbutaline, TCDD, or DMSO and plated in 12 well plates. For γ2b analysis cells were

21

plated at a concentration of 2.5x104 cells/ml, followed by a 48hr incubation period, while
cells used for Ig protein analysis were plated at 2.0x105 cells/ml, followed by a 24hr
incubation period. Cells were then centrifuged at 3000 rpm at 4°C for 5 min, and then
lysed with a mild lysis buffer with added protease inhibitors and frozen at -80˚C until
analysis.
At the time of analysis the cell lysates were thawed at room temperature and the
protein concentration determined by Bradford assay in order to standardize samples to
protein concentration. Standards for the Bradford were prepared with varying amounts of
Elga water, BSA, and 2μl of the mild lysis buffer plus protease inhibitor solution,
allowing for final standard concentrations ranging between 1-14μg of BSA and final
volumes of 800ul. 2μl of supernatant for each chemical sample were dispensed into
appropriately marked glass tubes with 798μl Elga water and 200μl Bradford reagent.
200μl of the standards and samples were added to 96-well plates followed by absorbance
readings on a plate reader (Molecular Devices, Spectramax plus 384).
The values calculated for the amount of protein in each sample were then used to
determine amounts of each sample needed to obtain 2μg of total protein for the ELISA
analysis of γ2b levels and Ig levels. The analysis was done by a standard sandwich
ELISA, in which the coating antibody and the detection antibody are specific for the
same antigen. The detection antibody is conjugated to HRP (horesradish peroxidase)
enzyme which cleaves a substrate producing a color change. Absorbance of the reaction
product will be determined by the plate reader previously mentioned above, using a
kinetic reading and standard curve to determine concentrations of γ2b and Ig.
E.

Statistics
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The mean ± S.E. was determined for each treatment group (n=3). To determine
statistical significance between treatment groups and vehicle controls, the data were
analyzed by a one-way ANOVA followed by a Dunnett´s two-tailed t-test. For IC50
generation, a complete concentration-response curve for each chemical was obtained.
Concentration-response curves were fit by a four-parameter logistic concentrationresponse equation given as Y = Bottom + (Top-Bottom)/(1+10^((LogIC50-X)*Hill
Slope)). X is the logarithm of concentration. Y is the response. The derived parameter,
IC50 was the nanomolar (nM) to micromolar (μM) concentration generating half-maximal
response. The IC50 value for each AhR activator was expressed as the average plus the
95% confidence interval which was generated from the best-fit value of the IC50
parameter between data sets (n=3 to 4).
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XII.

RESULTS
A.

Inhibition of LPS-induced 3’IgH RR activity by AhR ligands in

transiently transfected CH12.LX cells.
AhR binding within the 3’IgH RR has been previously identified, along with
inhibition of the 3’IgH RR by the AhR ligand TCDD. However, the role of the AhR in
this effect has not been determined. TCDD represents only a single chemical in a large
group of chemicals that can modulate AhR activity. Therefore, if the effect of TCDD on
3’IgH RR activity is AhR-dependent, than the 3’IgH RR may be targeted by a broad
group of chemicals. To determine if the modulation of the 3’IgH RR produced by TCDD
is a common effect of all AhR ligands, we examined four non-dioxin AhR ligands ICZ,
Primaquine, Carbaryl, and Omeprazole for their effect on luciferase activity in CH12.LX
B-cells transiently transfected with a luciferase reporter regulated by the 3’IgH RR.
These assays showed that similar to TCDD all four chemicals were capable of
suppressing LPS-induced 3’IgH RR activity in a concentration-dependent manner.
Inhibition of the 3’IgH RR by each chemical was concentration-dependent, with maximal
suppression (without deterioration of viability) occurring at the following concentrations:
ICZ-500nM, Primaquine-50μM, Carbaryl-100μM, and Omeprazole-62.5μM (Figure 3 AD). This assay was taken a step further to investigate if it is only the 3’IgH RR region
that is modulated or if the activity of the VH promoter is also affected. The VH promoter
lies upstream of the variable region and is responsible for initiation of transcription at
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theIg heavy chain (IgH) gene. The VH promoter transiently transfected into the same Bcell line was activated with LPS stimulation, but to a lesser degree than the 3’IgH RR
reporter. Also, the concentrations of the chemicals that inhibited 3’IgH RR activation
did not modulate the VH promoter (Figure 4 B).

Consistent with previous studies

identifying the sensitivity of activated versus resting B cells to TCDD (Marcus,
Holsapple et al. 1998; Sulentic, Holsapple et al. 1998; Crawford, Sulentic et al. 2003),
these AhR activators had no effect on background activity of 3’IgH RR (Figure 4 A).
B.

Inhibition of 3’IgH RR activity by structurally diverse AhR ligands

follows a structure activity relationship in CH12.LX cells stably expressing a
transgene regulated by the 3’IgH RR.
The transient transfection results supported further investigating the phenomenon
of 3’IgH RR inhibition by AhR agonists other that TCDD. While transient transfections
provide a quick way to obtain results, there can be considerable variation from
experiment to experiment. When transiently transfecting a plasmid into a cell you are not
guaranteed a certain amount of copies per cell or even that every cell will receive a copy.
Additionally, in transient transfections the 3’IgH RR reporter is not wrapped around
chromatin as is the case for endogenous genes. In order to more closely approximate the
situation on the IgH chromosome and to avoid the many limitations of transient
transfection experiments, an experimental model (CH12.γ2b-3’IgH) developed in
CH12.LX cells that stably expresses a γ2b heavy chain transgene under the regulation of
the 3’IgH RR was used (Shi and Eckhardt 2001).

The CH12.γ2b-3’IgH cell line

expresses the 3’IgH RR in the context of chromatin just like endogenous genes, and each
cell contains one copy of the γ2b transgene as determined by PCR analysis (Sulentic,
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CEW, unpublished results). These cells have also been characterized as IgA expressing
B cells and do not express endogenous γ2b or IgG2b as determined by flow cytometry
and ELISA. All of the AhR agonists suppressed the LPS-inducible transcription of the
γ2b transgene in the CH12.γ2b-3’IgH cells (Figure 5 A-D). In addition to the results of
this assay following the same tendency of down-regulation of the 3’IgH RR shown in the
transient transfection assay, the down-regulation of the γ2b gene between the different
chemicals followed a structure activity relationship to their AhR binding affinity (Figure
6). The rank order potency established by the IC50 showed that TCDD, as expected, has
the greatest potency in inhibiting γ2b transgene expression, followed by ICZ, Carbaryl,
Omeprazole, and Primaquine. This is relatively consistent with their affinities for the
AhR, based on past research. TCDD has been shown to have the greatest affinity
followed next by ICZ. Carbaryl, Primaquine, and Omeprazole, based on past research,
have similar affinities for the AhR.
C.

Endogenous Ig protein expression was suppressed by the AhR

agonists.
While the modulation of the 3’IgH RR may provide an important tool in
identifying AhR activators and other chemicals that may alter B cell function, it may not
correlate with an alteration of endogenous Ig expression. An important function of B
cells is to produce and secrete antibodies following an encounter with a foreign agent, as
in the case of LPS. As demonstrated above a diverse set of AhR agonists are capable of
suppressing the 3’IgH RR which is thought to regulate Ig expression. Therefore, it was
important to establish a relationship between the suppression of our 3’IgH RR models,
i.e. transient and stable reporters, and the effect on endogenous Ig protein expression. All
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of the AhR agonists suppressed the LPS-induced expression of endogenous IgA (Figure
7). Instead of secreted IgA, intracellular IgA was measured and standardized to total
protein concentration so as to avoid any confounding influences due to an effect of the
chemicals on cellular proliferation.
D.

Modulation of the 3’IgH RR and Ig protein expression by non-AhR

Agonists.
Up to this point the focus of this study was directed at AhR agonists, but it was
also important to examine the effects of non-AhR agonists since the 3’IgH RR is
regulated by several transcription factors which are likely activated through different
signaling pathways. We chose to evaluate the effects of Terbutaline and Carbachol in our
γ2b model since each activates a distinct signaling receptor and have been shown to
modulate B cell activation. Terbutaline is a β2-adrenergic receptor agonist and has been
shown to enhance Ig expression in activated B cells through induction of OCA-B binding
to the 3’IgH RR (Podojil, Kin et al. 2004; Podojil and Sanders 2005). Carbachol is an
agonist for muscarinic and nicotinic receptors and has been shown to increase the T-cell
dependent antibody forming cell response (Pruett, Han et al. 1992).

Our studies

demonstrated that Terbutaline up-regulated the expression of the γ2b transgene in LPSstimulated cells, while Carbachol had no effect (Figure 8 A-B). The up-regulation of the
transgene by terbutaline was concentration-dependent, with the greatest effect at a
concentration of 100μM. Terbulatine and Carbachol did not modulate the VH promoter
in LPS-stimulated cells (Figure 9 B). Terbutaline and Carbachol also had no affect on
background activity when evaluating the 3’IgH RR with the luciferase reporter (Figure 9
A) or the γ2b transgene reiterating the need for prior stimulation of the B cell (Figure 10
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A-B). We once again showed that the effects on the γ2b transgene expression in LPSstimulated cells mimicked the effects on Ig

protein expression with Terbutaline

increasing endogenous IgA protein expression in LPS-stimulated CH12.γ2b-3’IgH cells
and carbachol having no effect (Figure 11). These findings validate our model in its
ability to identify chemical-induced modulation of the 3’IgH RR, and the correlation
between 3’IgH RR regulation and endogenous IgA protein expression.
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XIII. DISCUSSION
This study focused on chemical-induced modulation of the 3’IgH RR which
appears to correlate with the effects of these chemicals on Ig expression. The 3’IgH RR
is composed of four separate hypersensitive regulatory domains (hs3, hs1,2, hs3B, hs4),
each one being active at different times through the lifespan of a B cell (Chauveau,
Pinaud et al. 1998). As mention previously the 3’IgH RR contains numerous regulatory
binding sites, including at least two functional DRE motifs (Sulentic, Holsapple et al.
2000). Previous studies within this lab have demonstrated TCDD-induced AhR-DRE
binding within the 3’IgH RR as well as inhibition of 3’IgH RR activity that correlated
with TCDD-induced inhibition of μ heavy chain expression and IgM secretion(Sulentic,
Holsapple et al. 2000; Sulentic, Zhang et al. 2004).
TCDD is the prototypical AhR ligand and represents a large class of aromatic
hydrocarbons. However, a major focus of the present study was to determine if inhibition
of 3’IgH RR activation applied to a diverse range of non-dioxin AhR activators. For
these studies we utilized the CH12.LX B-cell line that has been well-characterized in
regards to TCDD-induced inhibition of B cell function and to the function of the AhR
signaling pathway (Sulentic, Holsapple et al. 1998). We chose to evaluate the following
non-dioxin AhR activators: the dietary metabolite ICZ; the antimalarial drug primaquine;
the pesticide Carbaryl; and the proton pump inhibitor Omeprazole.

ICZ, Primaquine,

Carbaryl, and Omeprazole have all been shown to be AhR activators (Denison, Phelan et
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al. 1998; Pohjanvirta, Korkalainen et al. 2002; Backlund and Ingelman-Sundberg 2004;
Lemaire, Delescluse et al. 2004).

ICZ, which is a breakdown product of cruciferous

vegetables, has the greatest potential exposure to humans based on a daily consumption
of cruciferous vegetables. Primaquine is a common choice for the treatment of malaria
which is widespread in tropical and subtropical regions. Carbaryl exposure is not as
broad as some of the other chemicals, but it is specific to certain lines of work where
insecticides are needed. Finally, Omeprazole is a common pharmaceutical drug used in
the treatment of stomach acid related illnesses. Additionally, Omeprazole is unique
compared to the other chemicals in that it , as yet, not been shown to directly bind to the
AhR, but it does induce nuclear translocation of the AhR, DRE binding, and CYP1A1
induction in rat hepatocytes (Lemaire, Delescluse et al. 2004).
Consistently, our studies demonstrated that all four AhR activators were capable
of inhibiting LPS-induced 3’IgH RR activity and suppressing the production Ig protein.
This suggests that modulation of the 3’IgH RR is not specific to TCDD, but more likely
is a target of all AhR activators. Furthermore, the inhibition of γ2b transgene expression
in the CH12.γ2b-3’IgH cells followed a structure activity relationship for AhR binding or
activation affinity, further supporting a role of the AhR in the inhibition of 3’IgH RR
activity. These effects were dependent on activation of the B cell. This study focused on
LPS-induced B cell activation. There is a possibility that the inhibitory effects of the
AhR activators are specific to LPS stimulation; however, this is unlikely since several
groups have previously identified an inhibition of Ig secretion or the antibody forming
cell response by TCDD following B cell activation with other stimuli including T-cell
dependent stimuli (Holsapple, Morris et al. 1991) . Since B cells are most sensitive to
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TCDD during activation, the potential impairment of Ig expression by AhR activators in
humans will depend on the timing of chemical exposure in relation to an immune
response. Timing is also an important consideration when it comes to the inhibitory
properties of the AhR activators, both in humans and in vitro. In other words, the AhR
activators will likely need to be at an effective concentration prior to the initiation of an
antibody response. Indeed, previous times of addition studies with TCDD have identified
the critical window of exposure to be within the first 24 hr of stimulation (Tucker, Vore
et al. 1986) .
These results may have important implications to human health, particularly
considering that AhR ligands include a diverse group of chemicals and that humans may
be exposed to several AhR ligands simultaneously and perhaps under chronic conditions
that may contribute to reaching a threshold level of AhR activation perhaps leading to
inhibition of 3’IgH RR activation and Ig expression. However, it is also a possibility that
multiple AhR agonists may compete for AhR binding and potentially decrease the overall
effect particularly if a lower affinity AhR ligand is in excess of a higher affinity ligand.
An additional consideration is the half-life of the AhR ligands. If they have short halflives they may well be cleared from the body before they could induce
immunosuppressive properties, so for many agonists continuous exposure at high levels
may be necessary to induce immunosuppresive effects. Whether multiple AhR ligands in
vivo will induce additive, synergistic, or antagonistic effects has yet to be determined.
Furthermore, the fact that some AhR ligands are antagonists and have been identified in
fruit and vegetable extracts (Denison and Nagy 2003) further complicates predictions
regarding the overall effect on 3’IgH RR activity and Ig expression in humans potentially
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exposed to multiple AhR modulators.

Regardless, the 3’IgH RR has at least two

functional DRE sites and is a sensitive target of TCDD and other AhR modulating
chemicals. An additional caveat is that this study utilized the mouse 3’IgH RR which has
differences in structure and transcriptional regulation compared to the human 3’IgH RR.
However, both the mouse and human 3’IgH RR contain two DRE-like binding sites.
As stated previously ICZ is a breakdown product of cruciferous vegetables. ICZ
is catalyzed from indole-3-carbinol in the acid environment of the stomach, or produced
as a metabolic product of intestinal bacteria from trytophan (Chen, Riby et al. 1995). A
previous study showed that people who consume 100 grams of cruciferous vegetables a
day will in turn be producing 1.3μg of ICZ (Bjeldanes, Kim et al. 1991). Interestingly,
indole-3-carbinol is widely sold in health food stores as a dietary supplement which
increases the possibility of certain population groups, particularly vegetarians, reaching
blood concentrations of ICZ that could impact 3’IgH RR activity, even though there is
still debate over the potential toxicological relevance in humans due to the short half-life.
Omeprazole is the common choice of treatment for stomach acid related illnesses.
It is generally given in tablet form of up to 40mg, which can result in a plasma
concentration of more than 5.21μM (PDR 2006) which is approximately 10-fold lower
than the concentration inducing maximal inhibition of 3’IgH RR activation in vitro.
However, the accumulated plasma concentration following a multi-day administration
has not been defined. Furthermore, with pharmaceutical drugs there is no guarantee that
patients will not take a higher dose than is recommended or the possibility of errors in
doctor or pharmacy prescriptions.

Additionally, as stated above there may be co-
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exposure to other AhR activators that may contribute to reaching an effective
concentration to mediate an effect on 3’IgH RR activity and Ig expression.
Primaquine is a widely used treatment for malaria, while Carbaryl is used as an
insecticide. Malaria causes disease in approximately 400 million people every year and
kills between 1 and 3 million every year in Sub-Saharan Africa. Primaquine is usually
given in 15 or 30mg tablets for 14 days and studies have shown that after acute dosage of
15mg there was a peak concentration of 65.0 μM (Ward, Mihaly et al. 1985). This peak
concentration, combined with the possibility of bioaccumulation over the course of the
therapy may result in an effective concentration to suppress 3’IgH RR activity and Ig
expression. Furthermore, individuals living in third world countries, where malaria is
most prevalent, may already have decreased immune function due to malnutrition and/or
other factors; suppression of 3’IgH RR activation may further compromise an already
weakened immune system. Carbaryl on the other hand is more likely to affect a smaller
population, specifically individuals that directly apply the insecticide.

Studies have

shown that possible Carbaryl exposure of formulators and applicators can range from 5974mg/hr through the dermal route and up to 1mg/hr through respiration (Comer, Staiff et
al. 1975); however, the plasma concentration was not determined.

This leaves the

question of how much this chemical will have suppressive properties on the immune
system, but it stands to reason that if chronic exposure occurs, especially without proper
protective clothing, plasma concentrations could reach levels that might lead to an effect
on 3’IgH RR activation and immunocompetence.
Our model also detected chemical-induced enhancement of 3’IgH RR activation.
Terbutaline, which is a β2-adrenergic agonist, was able to potentiate LPS-induced 3’IgH
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RR activation and IgA protein expression. This demonstrates that our model is not
limited to detecting inhibition of 3’IgH RR activity by AhR ligands, but can also detect
chemicals using distinct cellular pathways that lead to the modulation of transcription
factors other than the AhR which regulate 3’IgH RR activity. Additionally, these results
show that the 3’IgH RR can be regulated in both directions. These results are consistent
with a previous study in which Terbutaline was shown to up regulate the 3’IgH RR in
primary B cells and provides further significance to the present study in that a different
stimulus other than LPS was used and that it was done in primary B cells (Podojil, Kin et
al. 2004; Podojil and Sanders 2005) This shows that 3’IgH RR regulation is not limited
to LPS activation, and that our B cell line model is representative of primary B cells. In
contrast to Terbutaline, the muscarinic and nicotinic agonist Carbachol did not alter
3’IgH RR activation suggesting many possibilities, including the following.

1)

Activation of cholinergic receptors does not directly activate the appropriate signaling
pathway to lead to 3’IgH RR modulation. 2) The appropriate co-stimuli were not present.
For example, in a previous study Carbachol was shown to increase the T-cell dependent
IgM response to sheep red blood cells. So Carbachol might be T-cell dependent in its
regulation of immune responses. 3) Cholinergic receptors may not be functional in
CH12.LX cells.
In summary, modulation of the 3’IgH RR is not limited to TCDD and appears to
be AhR-dependent. It is becoming increasingly evident that AhR ligands (agonist and
antagonists) are not restricted to industrial or environmental sources but include
therapeutic drugs and dietary components present in dietary supplements, fruits and
vegetables (Denison and Nagy 2003). Multiple sources of potential exposure to AhR
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ligands and accumulation may produce additive or synergistic activation of the AhR
signaling pathway therefore posing a potential risk to humans, particularly to toxic
responses such as B cell dysfunction, which may not occur when exposed to only one
source.

Additionally, regulation of the 3’IgH RR is not limited to AhR agonists, but

includes modulators of other signaling and transcriptional pathways therefore increasing
the potential array of chemicals that may modulate 3’IgH RR activity and affect
immunocompetence. We believe that our B cell model may provide a valuable screening
and mechanistic tool in identifying chemicals that can directly alter 3’IgH RR activity
and Ig expression which is of significance to human health and to the detection of
possible immunotoxicants.
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Figure 1. Aryl Hydrocarbon Receptor (AhR) signaling pathway. Regulation of
cytochrome P4501A1 (CYP1A1) through ligand-induced activation of the AhR signaling
pathway.
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Figure 3. Inhibition of the 3’IgH RR luciferase reporter by AhR activators.
CH12.LX cells were transiently transfected with the 3’IgH RR reporter plasmid then
treated with vehicle (VH, 0.01% DMSO for ICZ and Primaquine or 0.1% DMSO for
Carbaryl and Omeprazole) or varying concentrations of indolo(3,2,b)carbazole (ICZ) (A),
Primaquine (B), Carbaryl (C), or Omeprazole (D), in the presence of LPS (3 μg/ml) for
48hr. Luciferase enzyme activity is shown on the y-axis as relative light units, n=3. NA
denotes naïve control. Significance from VH control at p<0.05 (*) or p<0.01 (**) was
determined by a 1-way ANOVA and Dunnett’s post-hoc test.
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Figure 4. Regulation of the VH Promoter and the 3’IgH RR. CH12.LX cells were
transiently transfected with the 3’IgH RR plasmid (A) or the VH promoter plasmid (B)
then treated with vehicle (VH, 0.01% DMSO) or specific concentrations of ICZ,
Primaquine,Carbaryl, or Omeprazole, in the presence or absence of LPS (3 μg/ml) for
48hr. Luciferase enzyme activity is shown on the y-axis as relative light units, n=3. NA
denotes naïve control. Significance from VH control at p<0.05 (*) or p<0.01 (**) was
determined by a 1-way ANOVA and Dunnett’s post-hoc test.
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Figure 5. Inhibition of the γ2b transgene by AhR activators. Stably transfected
CH12.γ2b-3’IgH cells were treated with vehicle (VH, 0.01% DMSO for ICZ and
Primaquine and 0.1% DMSO for Carbaryl and Omeprazole) or varying concentrations of
indolo(3,2,b)carbazole (ICZ) (A), Primaquine (B), Carbaryl (C), or Omeprazole (D), in
the presence of LPS (3μg/ml) for 48hr. γ2b protein expression in the cell lysate was
determined by standard ELISA and standardized to 2μg of total protein. n=3 Significance
from VH control at p<0.05 (*) or p<0.01 (**) was determined by a 1-way ANOVA and
Dunnett’s post-hoc test.
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Figure 6. IC50 of AhR activators. Percent inhibition was calculated from 3 to 4 separate
concentration-response curves for each chemical (one representative curve shown) and fit
to a four-parameter logistic concentration-response equation to generate the average IC50
for each chemical. NA denotes naïve control.
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Figure 7. Altered IgA secretion correlated with effects on 3’IgH RR activity.
CH12.γ2b-3’IgH cells were treated with vehicle (VH, 0.01% DMSO for ICZ and
primaquine or 0.1% DMSO for carbaryl and omeprazole) or specific concentrations of
indolo(3,2,b)carbazole (ICZ), primaquine, carbaryl, or omeprazole, in the presence of
LPS (3 μg/ml) for 24hr. IgA protein expression in the cell lysate was determined by
standard ELISA and standardized to 2μg of total protein. n=3. NA denotes naïve control.
Significance from VH control at p<0.05 (*) or p<0.01 (**).

48

unstimulated
LPS stimulated

A.

B.

**

150

γ2b expression
(ng/2μg total protein)

γ2b expression
(ng/2μg total protein)

200

*

100
50
0
NA

LPS

0.1

1.0

10

50
40
30
20
10
0

100

μM Terbutaline

NA LPS 0.01 0.1 1.0

10

100

μM Carbachol

Figure 8. Inhibition of the γ2b transgene by non-AhR ligands. Stably transfected
CH12. γ2b-3’IgH cells were treated with varying concentrations of terbutaline (A),
carbachol (B) in the presence of LPS (3μg/ml) for 48hr. γ2b protein expression in the cell
lysate was determined by standard ELISA and standardized to 2μg of total protein. n=3.
Significance from LPS control at p<0.05 (*) or p<0.01 (**) was determined by a 1-way
ANOVA and Dunnett’s post-hoc test.
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Figure 9. Regulation of the VH Promoter and the 3’IgH RR. CH12.LX cells were
transiently transfected with the 3’IgH RR (A) or the VH Promoter plasmid (B) then
treated with vehicle (VH, 0.01% for TCDD) or specific concentrations of TCDD,
terbutaline, or carbachol in the presence or absence of LPS (3 μg/ml) for 48hr.
Luciferase enzyme activity is shown on the y-axis as relative light units, n=3. NA denotes
naïve control. Significance from NA (VH control for TCDD) (A) or from LPS (LPS+VH
control for TCDD) (B) at p<0.05 (*) or p<0.01 (**) was determined by a 1-way ANOVA
and Dunnett’s post-hoc test.
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Figure 10. Regulation of the γ2b transgene by Non-AhR ligands in unstimulated
CH12.γ2b-3’IgH cells. Stably transfected CH12.γ2b-3’IgH cells were treated with
varying concentrations of terbutaline (A), or carbachol (B) in the absence of LPSstimulation for 48hr. γ2b protein expression in the cell lysate was determined by standard
ELISA and standardized to 2μg of total protein. n=3. Significance from NA control at
p<0.05 (*) or p<0.01 (**) was determined by a 1-way ANOVA and Dunnett’s post-hoc
test.
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Figure 11. Altered IgA secretion correlated with effects on 3’IgH RR activity.
CH12.γ2b-3’IgH cells were treated with vehicle (VH, 0.01% DMSO for TCDD) or
specific concentrations TCDD, terbutaline, or carbachol in the presence of LPS (3 μg/ml)
for 24hr. IgA protein expression in the cell lysate was determined by standard ELISA
and standardized to 2μg of total protein. n=3. NA denotes naïve control. Significance
from NA or VH control at p<0.05 (*) or p<0.01 (**).
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